U.S. pharma large copyright scrapped two experimental weight loss tablets final 12 months—a when-day-to-day capsule, lotiglipron, resulting from elevated liver enzymes plus a twice-each day capsule, danuglipron, on account of solid side effects—but CEO Albert Bourla has claimed the company is decided to “Enjoy and earn” within the weight pr